Sanofi and Denali Therapeutics Collaborates to Develop & Commercialize Clinical Candidates for Neurology and Inflammatory Disorders
Shots:
- Denali to get $125M upfront plus milestones payments that can exceed $1B and will also receive royalties for DNL747 (ex-US & China) & DNL758 (WW). The profit/loss sharing will be divided equally and this partnership also includes pre-clinical RIPK1 inhibitor candidate
- Sanofi will fund DNL747 (P-Ib & P-II) & DNL747 in MS (multiple sclerosis)- ALS (amyotrophic lateral sclerosis) & systemic inflammatory diseases respectively. Alzheimer’s disease will be funded by Denali for DNL747. For neurology disorders Sanofi (70%) & Denali (30%) will jointly fund P-III trial
- DNL747 & DNL758 are being developed for targeting RIPK1 protein. DNL747 is currently evaluated in P-I while P-II will be expected to initiate in 2019
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
